---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-23-000137"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2023-09-19T23:59:59+00:00"
generated_at: "2026-06-10T13:31:59.240647+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BeiGene regains full global rights to tislelizumab after terminating Novartis license agreement

## Summary
- On September 17, 2023, BeiGene Switzerland and Novartis mutually terminated the Collaboration and License Agreement for tislelizumab, effective immediately.
- BeiGene regains full global rights to develop, manufacture, and commercialize tislelizumab with no royalty payments due to Novartis.
- Novartis may continue ongoing clinical trials and conduct future combination trials with tislelizumab subject to BeiGene's approval.
- Novartis will provide transition services including manufacturing, regulatory, safety, and clinical support for tislelizumab.
- The termination covers licensed territories: US, Canada, Mexico, EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, Japan.

## SEC filing metadata
- accession: 0001651308-23-000137
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2023-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000137/0001651308-23-000137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000137/bgne-20230917.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-23-000137
- JSON: https://secwatch.observer/filing/0001651308-23-000137.json
- Plain text: https://secwatch.observer/filing/0001651308-23-000137.txt

## Key facts
- Material Agreements
  BeOne Medicines Ltd. terminated Mutual Termination and Release Agreement with Novartis Pharma AG (effective 2023-09-17).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Novartis Pharma AG
  - Effective: 2023-09-17
  source text: On September 17, 2023, BeiGene Switzerland and Novartis entered into a Mutual Termination and Release Agreement (the “Agreement”) to mutually terminate the License Agreement, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000137/0001651308-23-000137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.